Healthcare

Singular's proposed share is about US$2.55 million (A$3.5 million) of a US$3.0 million State of Florida appropriation. The memorandum of understanding is non-binding, except that the parties must enter definitive agreements on the minimum terms it sets out.

4DMedical released its Appendix 4C and quarterly activity report for the three months ended 30 September 2026, the first quarter of its 2027 financial year. The respiratory imaging company reported unaudited operating revenue of A$2.3m, up 66% on the prior corresponding period, driven by …

Adheris runs patient engagement and medication adherence programmes for pharmaceutical companies. In its quarterly activities report and Appendix 4C for the three months to 30 September 2026, it reported revenue of US$6.4m. That was up 1.6% on the US$6.3m of the prior corresponding period.

ACCENT tests narmafotinib combined with the chemotherapy drugs gemcitabine and Abraxane in pancreatic cancer. The company cited an overall response rate of 36 per cent, or 42 per cent when unconfirmed responses are counted, and a complete response rate of 7.8 per cent.

The final Phase II Clinical Study Report from Southern Star Research, dated 1 October 2026, confirmed the interim results and completed the pharmacokinetic dataset agreed with the US Food and Drug Administration. Phase III is targeted to start in the first half of calendar …

Revenue for the nine months to 30 September was A$24.8 million, up 19 per cent, or 11 per cent in constant currency. Underlying EBITDA, which excludes foreign exchange and share-based payments, was A$0.6 million for the quarter, matching the prior period, and A$1.9 million …

Avecho Biotechnology Limited (ASX:AVE) has released its quarterly activities report and Appendix 4C for the quarter ended 30 September 2026. The key development was the restart of recruitment and dosing for the final cohort of its pivotal Phase III trial of a CBD capsule …